These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 26450123)
1. The JAK2 V617F Allele Burden in Latent Myeloproliferative Neoplasms Presenting with Splanchnic Vein Thrombosis. Goodyer M; Langabeer SE; Haslam K; Murphy K Pathol Oncol Res; 2016 Jan; 22(1):229-30. PubMed ID: 26450123 [No Abstract] [Full Text] [Related]
2. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis. Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270 [TBL] [Abstract][Full Text] [Related]
4. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report. Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519 [TBL] [Abstract][Full Text] [Related]
5. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. De Stefano V; Fiorini A; Rossi E; Za T; Farina G; Chiusolo P; Sica S; Leone G J Thromb Haemost; 2007 Apr; 5(4):708-14. PubMed ID: 17263783 [TBL] [Abstract][Full Text] [Related]
6. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis. De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212 [No Abstract] [Full Text] [Related]
7. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms. Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231 [No Abstract] [Full Text] [Related]
8. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis. Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189 [TBL] [Abstract][Full Text] [Related]
9. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Pardanani A; Lasho TL; Schwager S; Finke C; Hussein K; Pruthi RK; Tefferi A Leukemia; 2007 Aug; 21(8):1828-9. PubMed ID: 17460706 [No Abstract] [Full Text] [Related]